Vascular endothelial factor receptor 2 (VEGFR-2) is an attractive target for cancer drugs because inhibiting it prevents tumors from developing the blood vessels that they require for rapid growth.

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

A schematic illustration of the role of DHHC5 and CRYBG1 in controlling lacteal function and intestinal lipid absorption by maintaining the lipid raft association of VEGFR2. The proper functioning ...

Akeso is on a winning streak. Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for its PD-1 inhibitor penpulimab co ...

BNT327 showed a high binding affinity to PD-L1 and VEGF-A and efficient blocking of PD-1/PD-L1 and VEGF-A/VEGFR2 signaling. Anti-tumor activity superior to single PD-1/PD-L1 blockade or anti-VEGF ...

VXM01 is an oral, live-attenuated bacterial vaccine engineered to express VEGFR2, inducing a targeted cytotoxic T-cell response. VXM01's T cells target and destroy VEGFR2-expressing cells within the ...

It is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to carry vascular endothelial growth factor receptor-2 (VEGFR2) as the target gene. VXM01 ...

BR55 was safe and highly accurate (>95%) at marking VEGFR2 expression in patients with breast, ovarian and thyroid cancer, as well as Crohn disease. The Food and Drug Administration (FDA ...

a PD1-VEGFR2 bifunctional antibody called jankistomig. The company has plans to submit an IND filing in “late 2025” for the candidate, which is designed to target immune checkpoint inhibition ...

In a poster titled, "Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD-1 inhibition in preclinical models of CLDN18.2-expressing cancers," Elevation Oncology will present ...

"We are pleased to share preclinical data supporting our planned evaluation of EO-3021 in combination with VEGFR2 or PD-1 inhibitors," said David Dornan, Ph.D., Chief Scientific Officer of ...